Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Current Deferred Revenue: 2011-2024

Historic Current Deferred Revenue for Niagen Bioscience (NAGE) over the last 10 years, with Dec 2024 value amounting to $611,000.

  • Niagen Bioscience's Current Deferred Revenue rose 58.70% to $292,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $292,000, marking a year-over-year increase of 58.70%. This contributed to the annual value of $611,000 for FY2024, which is 213.33% up from last year.
  • As of FY2024, Niagen Bioscience's Current Deferred Revenue stood at $611,000, which was up 213.33% from $195,000 recorded in FY2023.
  • In the past 5 years, Niagen Bioscience's Current Deferred Revenue ranged from a high of $611,000 in FY2024 and a low of $157,000 during FY2022.
  • Moreover, its 3-year median value for Current Deferred Revenue was $195,000 (2023), whereas its average is $321,000.
  • Per our database at Business Quant, Niagen Bioscience's Current Deferred Revenue plummeted by 42.09% in 2021 and then surged by 213.33% in 2024.
  • Niagen Bioscience's Current Deferred Revenue (Yearly) stood at $278,000 in 2020, then crashed by 42.09% to $161,000 in 2021, then declined by 2.48% to $157,000 in 2022, then climbed by 24.20% to $195,000 in 2023, then soared by 213.33% to $611,000 in 2024.